scholarly journals Development and verification of a test rig for inactivation of bacteria and (corona-) viruses by UVC air disinfection systems

2021 ◽  
Vol 7 (2) ◽  
pp. 315-318
Author(s):  
Johannes Knaus ◽  
Petra Vatter ◽  
Martin Hessling
Keyword(s):  
Sampling Period ◽  
Load Reduction ◽  
Test Rig ◽  
Staphylococcus Carnosus ◽  
Viral Load Reduction ◽  
Highly Sensitive ◽  
Air Disinfection ◽  
Airborne Viruses ◽  
Corona Viruses ◽  
Inactivation Of Bacteria

Abstract The ongoing coronavirus pandemic spreads through airborne transmission and is therefore difficult to contain. However, coronaviruses are highly sensitive to UVC, so UVC air disinfection systems should be able to inactivate the virus. Unfortunately, so far there are only few possibilities to test the reduction of airborne viruses or other pathogens. A special test rig, which mainly consisted of a nebulizer and an airflow system, was developed to determine the antiviral and antibacterial efficiency of UVC air disinfection systems. In the assessment of such an UVC air disinfection system with nebulized Staphylococcus carnosus and a sampling period of 30 minutes, a mean bactericidal reduction of 3.70 log10 (99.98 %) was determined. For antiviral irradiation of the coronavirus surrogate phi6 a mean viral load reduction of 1.18 log10 (93.40 %) was observed after a sampling period of 10 minutes. Therefore, mobile UVC air disinfection systems could be applied in hospitals, retirement and nursing homes.

scholarly journals Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)

Viruses ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 628 ◽  
Author(s):  
Shuofeng Yuan ◽  
Chris Chun-Yiu Chan ◽  
Kenn Ka-Heng Chik ◽  
Jessica Oi-Ling Tsang ◽  
Ronghui Liang ◽  
...  
Keyword(s):  
Viral Load ◽  
Broad Spectrum ◽  
Viral Antigen ◽  
Treatment Options ◽  
Antiviral Agents ◽  
Antigen Expression ◽  
Load Reduction ◽  
Primary Screening ◽  
Viral Load Reduction ◽  
Antiviral Activities

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) signals an urgent need for an expansion in treatment options. In this study, we investigated the anti-SARS-CoV-2 activities of 22 antiviral agents with known broad-spectrum antiviral activities against coronaviruses and/or other viruses. They were first evaluated in our primary screening in VeroE6 cells and then the most potent anti-SARS-CoV-2 antiviral agents were further evaluated using viral antigen expression, viral load reduction, and plaque reduction assays. In addition to remdesivir, lopinavir, and chloroquine, our primary screening additionally identified types I and II recombinant interferons, 25-hydroxycholesterol, and AM580 as the most potent anti-SARS-CoV-2 agents among the 22 antiviral agents. Betaferon (interferon-β1b) exhibited the most potent anti-SARS-CoV-2 activity in viral antigen expression, viral load reduction, and plaque reduction assays among the recombinant interferons. The lipogenesis modulators 25-hydroxycholesterol and AM580 exhibited EC50 at low micromolar levels and selectivity indices of >10.0. Combinational use of these host-based antiviral agents with virus-based antivirals to target different processes of the SARS-CoV-2 replication cycle should be evaluated in animal models and/or clinical trials.

scholarly journals Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine

2021 ◽  
Author(s):  
Matan Levine-Tiefenbrun ◽  
Idan Yelin ◽  
Hillel Alapi ◽  
Rachel Katz ◽  
Esma Herzel ◽  
...  
Keyword(s):  
Viral Load ◽  
Real Life ◽  
Load Reduction ◽  
Protective Effects ◽  
Breakthrough Infection ◽  
Life Effectiveness ◽  
Post Vaccination ◽  
Viral Loads ◽  
Booster Vaccine ◽  
Viral Load Reduction

The BNT162b2 vaccine showed high real-life effectiveness both at preventing disease and in reducing viral loads of breakthrough infections, but coincidental with the rise of the Delta-variant SARS-CoV2, these protective effects have been decreasing, prompting a third, booster, vaccine inoculation. Here, analyzing viral loads of over 11,000 infections during the current wave in Israel, we find that even though this wave is dominated by the Delta-variant, breakthrough infections in recently vaccinated patients, still within 2 months post their second vaccine inoculation, do have lower viral loads compared to unvaccinated patients, with the extent of viral load reduction similar to pre-Delta breakthrough observations. Yet, this infectiousness protection starts diminishing for patients two months post vaccination and ultimately vanishes for patients 6 months or longer post vaccination. Encouragingly, we find that this diminishing vaccine effectiveness on breakthrough infection viral loads is restored following the booster vaccine. These results suggest that the vaccine is initially effective in reducing infectiousness of breakthrough infections even with the Delta variant, and that while this protectiveness effect declines with time it can be restored, at least temporarily, with a booster vaccine.

Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination

Vaccine ◽  
2012 ◽  
Vol 30 (19) ◽  
pp. 2943-2950 ◽  
Author(s):  
Christoph S. Klade ◽  
Elisabeth Schuller ◽  
Thomas Boehm ◽  
Alexander von Gabain ◽  
Michael P. Manns
Keyword(s):  
Viral Load ◽  
Load Reduction ◽  
Genotype 1 ◽  
Peptide Vaccination ◽  
Hcv Genotype ◽  
Therapeutic Peptide ◽  
Viral Load Reduction ◽  
Treatment Naïve ◽  
Hcv Genotype 1

Circulating Tregs Correlate with Viral Load Reduction in Chronic HBV-Treated Patients with Tenofovir Disoproxil Fumarate

2011 ◽  
Vol 31 (3) ◽  
pp. 509-520 ◽  
Author(s):  
Nirupma TrehanPati ◽  
Shyam Kotillil ◽  
Syed S. Hissar ◽  
Shikha Shrivastava ◽  
Arshi Khanam ◽  
...  
Keyword(s):  
Viral Load ◽  
Tenofovir Disoproxil Fumarate ◽  
Load Reduction ◽  
Viral Load Reduction ◽  
Chronic Hbv

scholarly journals 504. Case SEries: Nasal Antimicrobial Photodisinfection (APDT) as Treatment Protocol for Asymptomatic and Early Stage COVID-19 Patients

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S354-S354
Author(s):  
Jack Kolenda ◽  
Josepmaria Argemi
Keyword(s):  
Viral Load ◽  
Treatment Time ◽  
Respiratory Infections ◽  
Early Stage ◽  
Treatment Protocol ◽  
Case Series ◽  
Load Reduction ◽  
Safety Issues ◽  
Viral Load Reduction ◽  
Before And After

Abstract Background Targeted reduction of SARS-CoV-2 viral load in the nose may mitigate the severity of lower tract respiratory disease as well as reduce hospitalization and mortality rates. Nasal Photodisinfection has been deployed for 10 years in Canadian hospitals reducing post-surgical infections. The objective of thiswork was to demonstrate effectiveness of APDT in early stage COVID-19 and asymptomatic carriers. Methods A cohort of 40 COVID-19 positive patients were treated with nasal photodisinfection (Steriwave) at a private clinic. All patients were previously identified by PCR as SARS-CoV-2 positive and admitted into the treatment cohort. BD rapid antigen nares testing was used before and after Photodisinfection treatment. Of the 40 patients, 13 were female and 27 were male. Age range was 9- 56 years of age. Treatment involved 3-4 applications of photosensitizer and 16-24 minutes per patient of treatment time. Patients were followed up within 24 hours, 48 hours as well as day 5 and 6 and day 10/11. Patients filled out a COVID-19 score card. Results Results demonstrated APDT was capable of significant and rapid viral load reduction in COVID-19 carriers. 100% of patients were converted from positive rapid antigen test to negative. 60% of patients reported fever resolution within 24 hours. Fever resolution occurred in 100% of patients within 48hours. Moreover, results demonstrated accelerated resolution of COVID-19 symptoms and significantly improved mental health benefits from reduction of COVID-19 related stress and anxiety. None of the patients experienced severe symptoms and no patients were hospitalized. Safety outcomes demonstrated no patient safety issues with only minor transient side effects (rhinorrhea, sneezing) observed. Moreover, the treatment procedure was pain-free and well tolerated by all patients. Conclusion Photodisinfection-based nasal decolonization anti-viral efficacy was demonstrated with improved outcomes for all patients treated in this case series. Significant rapid viral load reduction was confirmed by rapid antigen tests in all patients. More clinical studies are warranted in support of Photodisinfection based therapy for upper respiratory infections such as COVID-19. Disclosures All Authors: No reported disclosures

Sign in / Sign up

Export Citation Format

Share Document